Ethics of paediatric end-of-life decision making and consent for publication
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Outcome of goal-directed non-invasive ventilation and mechanical insufflation/exsufflation in spinal muscular atrophy type I
- Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1–3
- Nusinersen for SMA: expanded access programme
- British Thoracic Society guideline for respiratory management of children with neuromuscular weakness
- Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review
- The best interests test at the end of life on PICU: a plea for a family centred approach
- Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial)
- Infantile spinal muscular atrophy variant with congenital fractures in a female neonate: evidence for autosomal recessive inheritance
- Spinal muscular atrophy: untangling the knot?
- Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4